Haemonetics.
company based in Braintree, Massachusetts, USA
- Reports this week
- 0
- Active events
- 0
- Connections
- 50
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Haemonetics CEO Chris Simon reflected on the company's performance on August 8, 2026.Some support2 reports
-
Haemonetics announced that it funded a study being conducted at Emory University.Some support1 report
-
Bank of America and Mizuho issued rating changes and price targets for Haemonetics on August 1, 2026.Some support1 report
-
Jin Medical International and Haemonetics are medical companies competing in the market, with Jin Medical International based in Changzhou.Some support1 report
-
Analysts compared the business models and market performance of Haemonetics and Curaleaf.Some support1 report
-
Citi initiated positive catalyst watch on Haemonetics and GE Healthcare in the MedTech sector.Some support2 reports1 development inside
-
Rothschild advises buying when there is blood on the streets regarding Haemonetics.Speculative1 report
-
Financial analysts, including Needham & Company, Mizuho Financial Group, and Marie Thibault, questioned Haemonetics' long-term growth and product performance.Speculative1 report
-
Wolfe initiated coverage on July 9, 2025, giving an Outperform rating, noting that both Better and Haemonetics benefit from the AI deployment secular shift.Speculative1 report
-
UnitedHealth Group, ICU Medical, and Haemonetics integrated their supply chains with Canada for pharmaceuticals and medical devices.Some support1 report
-
Haemonetics is based in Braintree, Massachusetts.Some support2 reports
-
Zacks Investment Research published stock analysis reports concerning Haemonetics on August 7, 2025.Some support1 report
-
Haemonetics was classified into the Zacks Medical - Products industry as of August 7, 2025.Some support1 report
-
Haemonetics reported financial results for August 2025, noting that the rest of Asia contributed 6.7% of its total revenue.Some support1 report
-
Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Haemonetics this week
News at the entities that move Haemonetics most-
Food and Drug Administration StructuralThe Food and Drug Administration approved Bayer's new blood thinner on November 9th.Moves Haemonetics
-
New York Stock Exchange Shared contextLazard Asset Management LLC lifted its position in the stock of General American Investors, Inc., which is listed on the NYSE.Moves Haemonetics
-
Citigroup Mentioned togetherCantor Fitzgerald and Citigroup restated positive rating upgrades for Sagimet Biosciences.Moves Haemonetics
-
Bank of America Mentioned togetherBank of America and Citigroup adjusted target prices and raised price objectives for BDX stock.Moves Haemonetics
-
Curaleaf Mentioned togetherEllsworth ordinance allows Curaleaf conversion, and the company's building is located near Camden National Bank.Moves Haemonetics
-
Manufacturers Life Insurance Company TransactionalGeode Capital Management, Mizuho Securities, and Manufacturers Life Insurance Company increased their holdings and raised their target price/rating on MBX Biosciences stock.Moves Haemonetics
Connections
The 17 strongest of 50, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Christopher Simon Structural
Christopher Simon serves as the CEO of Haemonetics, guiding its core product focus and platforms.
-
CSL Limited Structural
CSL Limited has established a supply agreement and plans to use Haemonetics' devices for plasma collection.
-
Chris Simon Structural
Chris Simon serves as the President and CEO of Haemonetics.
-
Emory University Transactional
Haemonetics provided financial support for a study being conducted at Emory University.
-
CSL Plasma Structural
Haemonetics supplies critical systems to CSL Plasma, establishing a vendor-client structural relationship in the plasma processing industry.
-
Food and Drug Administration Structural
The FDA granted regulatory approval for a product manufactured by Haemonetics.
-
Plasma Operational
The plasma market segment drives the financial performance and revenue results of Haemonetics.
-
Chris Simon Structural
Chris Simon serves as the CEO of Haemonetics, providing executive leadership and direction for the company.
Show all 17 connections
-
New York Stock Exchange Shared context
Haemonetics shares are traded on the New York Stock Exchange, placing the company within the exchange's market context.
-
Citigroup Mentioned together
Citigroup provided a buy rating on Haemonetics.
-
Bank of America Mentioned together
Bank of America provided a stock rating and price target for Haemonetics.
-
Curaleaf Mentioned together
Analysts compared the business models and market performance of Haemonetics and Curaleaf.
-
Mizuho Mentioned together
Mizuho assessed Haemonetics by raising its price target and giving an outperform rating.
-
Manufacturers Life Insurance Company Transactional
A single snapshot indicates a transactional event involving the purchase of company shares between the two entities.
-
Boston Shared context
Haemonetics is located in the Boston metropolitan area.
-
MarketBeat Mentioned together
No evidence found in the provided timeline to establish a relationship between MarketBeat and Haemonetics.
-
Persona Mentioned together
No evidence of a relationship between Persona and Haemonetics was found in the provided timeline.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventAugust 2026
3 eventsShow 1 earlier month
June 2026
13 events- Integer and Bausch + Lomb are identified as companies operating in the medical devices & supplies segment.
- Jin Medical International and Haemonetics are medical companies competing in the market, with Jin Medical International based in Changzhou.
- Analysts compared the business models and market performance of Haemonetics and Curaleaf.
- Citi initiated positive catalyst watch on Haemonetics and GE Healthcare in the MedTech sector.
- Rothschild advises buying when there is blood on the streets regarding Haemonetics.
- Financial analysts, including Needham & Company, Mizuho Financial Group, and Marie Thibault, questioned Haemonetics' long-term growth and product performance.
- Wolfe initiated coverage on July 9, 2025, giving an Outperform rating, noting that both Better and Haemonetics benefit from the AI deployment secular shift.
- UnitedHealth Group, ICU Medical, and Haemonetics integrated their supply chains with Canada for pharmaceuticals and medical devices.
- Haemonetics is based in Braintree, Massachusetts.
- Zacks Investment Research published stock analysis reports concerning Haemonetics on August 7, 2025.
- Haemonetics was classified into the Zacks Medical - Products industry as of August 7, 2025.
- Haemonetics reported financial results for August 2025, noting that the rest of Asia contributed 6.7% of its total revenue.
- Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.